Prostaglandin D2 pathway upregulation: Relation to asthma severity, control, and TH2 inflammation

2000, Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions, Am J Respir Crit Care Med, 162, 2341, 10.1164/ajrccm.162.6.ats9-00

National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 3 (EPR3). Bethesda (MD): National Institutes of Health/National Heart, Lung, and Blood Institute; 2007. Publication no. 08-4051. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed January 16, 2012.

Moore, 2007, National Heart, Lung, Blood Institute’s Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program, J Allergy Clin Immunol, 119, 405, 10.1016/j.jaci.2006.11.639

Balzar, 2005, Relationship of small airway chymase-positive mast cells and lung function in severe asthma, Am J Respir Crit Care Med, 171, 431, 10.1164/rccm.200407-949OC

Wenzel, 2007, IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression, Am J Respir Crit Care Med, 175, 570, 10.1164/rccm.200607-909OC

Balzar, 2011, Mast cell phenotype, location, and activation in severe asthma: data from the severe asthma research program, Am J Respir Crit Care Med, 183, 299, 10.1164/rccm.201002-0295OC

Galli, 2005, Mast cells in the development of adaptive immune responses, Nat Immunol, 6, 135, 10.1038/ni1158

Kanaoka, 2000, Structure and chromosomal localization of human and mouse genes for hematopoietic prostaglandin D synthase. Conservation of the ancestral genomic structure of sigma-class glutathione S-transferase, Eur J Biochem, 267, 3315, 10.1046/j.1432-1327.2000.01362.x

Herlong, 2006, Positioning prostanoids of the D and J series in the immunopathogenic scheme, Immunol Lett, 102, 121, 10.1016/j.imlet.2005.10.004

Pettipher, 2007, Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases, Nat Rev Drug Discov, 6, 313, 10.1038/nrd2266

Nantel, 2004, Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa, Prostaglandins Other Lipid Mediat, 73, 87, 10.1016/j.prostaglandins.2003.12.002

Okano, 2006, Presence and characterization of prostaglandin D2-related molecules in nasal mucosa of patients with allergic rhinitis, Am J Rhinol, 20, 342, 10.2500/ajr.2006.20.2865

Abonia, 2010, Involvement of mast cells in eosinophilic esophagitis, J Allergy Clin Immunol, 126, 140, 10.1016/j.jaci.2010.04.009

Tanaka, 2004, Effects of prostaglandin D2 on helper T cell functions, Biochem Biophys Res Commun, 316, 1009, 10.1016/j.bbrc.2004.02.151

Gosset, 2005, Prostaglandin D2 affects the differentiation and functions of human dendritic cells: impact on the T cell response, Eur J Immunol, 35, 1491, 10.1002/eji.200425319

Stebbins, 2010, Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation, Eur J Pharmacol, 638, 142, 10.1016/j.ejphar.2010.04.031

Barnes, 2012, A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma, Clin Exp Allergy, 42, 38, 10.1111/j.1365-2222.2011.03813.x

Singh, 2012, Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459, Eur Respir J, 41, 46, 10.1183/09031936.00092111

Fajt, 2010, Elevated prostaglandin D2 (PGD2) levels in bronchoalveolar lavage fluid (BALF) in severe asthma, J Allergy Clin Immunol, 125, AB43, 10.1016/j.jaci.2009.12.202

Fajt, 2010, Epithelial hematopoietic prostaglandin (PG) D synthase is increased in asthma, Am J Respir Crit Care Med, 181, A1440

Fajt, 2011, CRTH2 receptor and its ligand, PGD2, are increased in severe asthma, Am J Respir Crit Care Med, 183, A4446

Juniper, 1992, Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials, Thorax, 47, 76, 10.1136/thx.47.2.76

Moore, 2011, National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Safety of investigative bronchoscopy in the Severe Asthma Research Program, J Allergy Clin Immunol, 128, 328, 10.1016/j.jaci.2011.02.042

Chibana, 2008, IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells, Clin Exp Allergy, 38, 936, 10.1111/j.1365-2222.2008.02969.x

Corren, 2011, Lebrikizumab treatment in adults with asthma, N Engl J Med, 365, 1088, 10.1056/NEJMoa1106469

Pavord, 2012, Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, Lancet, 380, 651, 10.1016/S0140-6736(12)60988-X

Mahmud, 1997, Prostaglandin D synthase in human megakaryoblastic cells, J Biol Chem, 272, 28263, 10.1074/jbc.272.45.28263

Fujimori, 2000, Transcriptional activation of the human hematopoietic prostaglandin D synthase gene in megakaryoblastic cells. Roles of the oct-1 element in the 5'-flanking region and the AP-2 element in the untranslated exon 1, J Biol Chem, 275, 40511, 10.1074/jbc.M007688200

Luna-Gomes, 2011, Eosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation, J Immunol, 187, 6518, 10.4049/jimmunol.1101806

Philip, 2009, Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis, J Allergy Clin Immunol, 124, 942, 10.1016/j.jaci.2009.07.006

Xue, 2005, Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells, J Immunol, 175, 6531, 10.4049/jimmunol.175.10.6531

Pettipher, 2012, Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils, J Pharmacol Exp Ther, 340, 473, 10.1124/jpet.111.187203

Busse, 2013, Safety and efficacy of the prostaglandin D(2) receptor antagonist AMG 853 in asthmatic patients, J Allergy Clin Immunol, 131, 339, 10.1016/j.jaci.2012.10.013

Dougherty, 2010, Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma, J Allergy Clin Immunol, 125, 1046, 10.1016/j.jaci.2010.03.003

Moore, 2007, National Heart, Lung, Blood Institute’s Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program, J Allergy Clin Immunol, 119, 405, 10.1016/j.jaci.2006.11.639

Balzar, 2011, Mast cell phenotype, location, and activation in severe asthma: data from the severe asthma research program, Am J Respir Crit Care Med, 183, 299, 10.1164/rccm.201002-0295OC

National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 3 (EPR3). Bethesda (MD): National Institutes of Health/National Heart, Lung, and Blood Institute; 2007. Publication no. 08-4051. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed January 16, 2012.

Juniper, 1992, Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials, Thorax, 47, 76, 10.1136/thx.47.2.76

Moore, 2011, National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Safety of investigative bronchoscopy in the Severe Asthma Research Program, J Allergy Clin Immunol, 128, 328, 10.1016/j.jaci.2011.02.042